Related Experiment Video

Updated: Jul 17, 2026

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

Dendritic cell vaccine strategies for renal cell carcinoma

Dolores J Schendel1

  • 1GSF National Research Center for Environment and Health, Institute of Molecular Immunology and the Clinical Cooperation Group Immune Monitoring, Marchioninistrasse 25, 81377 Munich, Germany. schendel@gsf.de

Expert Opinion on Biological Therapy
|January 26, 2007
PubMed

Insights

Dendritic cell (DC) vaccines show promise for kidney cancer but need improvement. Enhancing antigen delivery and IL-12 secretion can boost efficacy, alongside therapies for immune suppression.

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular immunology

Background:

  • Dendritic cell (DC) vaccines are under investigation for renal cell carcinoma (RCC).
  • Current DC vaccine strategies demonstrate safety but limited clinical efficacy.
  • Evolving DC biology understanding informs vaccine development.

Purpose of the Study:

  • To review current dendritic cell vaccine strategies for renal cell carcinoma.
  • To identify key areas for improving DC vaccine quality and clinical efficacy.
  • To discuss the role of IL-12 and combination therapies in enhancing antitumor responses.

Main Methods:

  • Review of current literature on dendritic cell vaccine development for RCC.
  • Analysis of factors influencing DC vaccine immunogenicity and clinical outcomes.
  • Exploration of strategies to overcome immune suppression in advanced cancer.

Main Results:

  • Mature DCs are crucial to prevent regulatory T cell induction.
  • Improved antigen sources and loading enhance DC vaccine quality.
  • IL-12 secretion by DCs promotes T helper type 1 responses and antitumor immunity.

Conclusions:

  • Optimizing DC vaccine quality through antigen delivery and IL-12 production is key.
  • Combination therapies addressing systemic immune suppression are essential for advanced RCC.
  • Further research is needed to translate improved DC vaccine strategies into significant clinical benefits.

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.